Drug profile · INN
fostemsavir
RUKOBIA
fostemsavir (RUKOBIA) is a envelope polyprotein gp160 inhibitor.
EMA: approved Antiinfectives for systemic use (J05) J05AX
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — fostemsavir
- Class
- Antiinfectives for systemic use (J05)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
fostemsavir (RUKOBIA) is a envelope polyprotein gp160 inhibitor.
Key facts
INN fostemsavir
Brand RUKOBIA
Mechanism Envelope polyprotein GP160 inhibitor
Target Envelope glycoprotein gp160
Therapeutic class Antiinfectives for systemic use (J05)
ATC code J05AX
Mechanism of action
Envelope polyprotein GP160 inhibitor
Primary target: Envelope glycoprotein gp160
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fostemsavir?
fostemsavir (RUKOBIA) is a envelope polyprotein gp160 inhibitor.
What is the brand name for fostemsavir?
RUKOBIA is a marketed brand name for fostemsavir. Check FDA Drugs@FDA for the current US label holder and prescribing information.